Esperion Therapeutics (ESPR) News Today $2.21 +0.03 (+1.38%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$2.22 +0.01 (+0.27%) As of 05:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Nuveen LLC Buys Shares of 3,087,700 Esperion Therapeutics, Inc. $ESPR3 hours ago | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Lowered to "Hold" Rating by Wall Street ZenAugust 27 at 3:22 AM | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 27 at 3:21 AM | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Downgraded to Hold Rating by Wall Street ZenAugust 26 at 2:47 AM | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 25, 2025 | americanbankingnews.comEsperion Therapeutics’ Earnings Call Highlights GrowthAugust 23, 2025 | theglobeandmail.comAre Options Traders Betting on a Big Move in Esperion Therapeutics Stock?August 22, 2025 | msn.comEsperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by Wall Street ZenAugust 19, 2025 | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Upgraded at Wall Street ZenAugust 18, 2025 | marketbeat.comHeadlands Technologies LLC Sells 216,619 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)August 14, 2025 | marketbeat.comEsperion Delays Q2 2025 Financial Report FilingAugust 11, 2025 | msn.comEsperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at Wall Street ZenAugust 10, 2025 | marketbeat.comFY2025 EPS Estimates for ESPR Increased by Cantor FitzgeraldAugust 9, 2025 | marketbeat.comHC Wainwright Has Bullish Estimate for ESPR Q3 EarningsAugust 9, 2025 | marketbeat.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 7, 2025 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Announces Quarterly Earnings ResultsAugust 6, 2025 | marketbeat.comEsperion (ESPR) Q2 Revenue Jumps 12%August 5, 2025 | fool.comEsperion rises after revenue beat, Q1 profitability expectationAugust 5, 2025 | seekingalpha.comEsperion Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 5, 2025 | globenewswire.comWhat is Zacks Research's Forecast for ESPR Q1 Earnings?July 31, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 31, 2025 | marketbeat.comEquities Analysts Offer Predictions for ESPR FY2027 EarningsJuly 30, 2025 | marketbeat.comEsperion Therapeutics soars amid vague takeover speculationJuly 24, 2025 | msn.comEsperion Therapeutics (NASDAQ:ESPR) Stock Passes Below 200-Day Moving Average - What's Next?July 23, 2025 | marketbeat.comEsperion to Report Second Quarter 2025 Financial Results on August 5July 22, 2025 | globenewswire.comWhat is Zacks Research's Forecast for ESPR FY2025 Earnings?July 14, 2025 | marketbeat.comWhat is Zacks Research's Estimate for ESPR FY2027 Earnings?July 11, 2025 | marketbeat.comEsperion settles litigation with Accord HealthcareJuly 10, 2025 | msn.comEsperion Therapeutics (NASDAQ:ESPR) Share Price Passes Above 50 Day Moving Average - Should You Sell?July 2, 2025 | marketbeat.comEsperion Appoints Craig Thompson to Board of DirectorsJuly 1, 2025 | globenewswire.comHC Wainwright Issues Optimistic Forecast for ESPR EarningsJune 19, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)June 17, 2025 | marketbeat.comCan The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?June 14, 2025 | seekingalpha.comResearch Analysts Offer Predictions for ESPR FY2026 EarningsJune 11, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 11, 2025 | marketbeat.comTraders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)June 9, 2025 | marketbeat.comQ2 EPS Forecast for Esperion Therapeutics Lifted by AnalystJune 6, 2025 | marketbeat.comMillennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)June 3, 2025 | marketbeat.comDeutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)June 1, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DEJune 1, 2025 | marketbeat.comZacks Research Has Pessimistic Outlook of ESPR Q2 EarningsMay 31, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLCMay 31, 2025 | marketbeat.comWhat is Zacks Research's Forecast for ESPR FY2027 Earnings?May 30, 2025 | marketbeat.comWoodline Partners LP Has $3.31 Million Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)May 27, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of "Moderate Buy" by BrokeragesMay 19, 2025 | marketbeat.comEsperion Settles Patent Litigation With Micro Labs For Generic NexletolMay 14, 2025 | nasdaq.comEsperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040May 12, 2025 | globenewswire.comHC Wainwright Issues Pessimistic Outlook for ESPR EarningsMay 11, 2025 | marketbeat.comEsperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor ConferenceMay 9, 2025 | theglobeandmail.comEsperion Therapeutics (NASDAQ:ESPR) Price Target Lowered to $4.00 at Needham & Company LLCMay 9, 2025 | marketbeat.com Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.501.03▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼74▲ESPR Articles Average Week Get the Latest News and Ratings for ESPR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Apogee Therapeutics News Today Beam Therapeutics News Today Twist Bioscience News Today Immunocore News Today Cidara Therapeutics News Today Aurinia Pharmaceuticals News Today Biohaven News Today WAVE Life Sciences News Today Travere Therapeutics News Today Tilray Brands News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access